Company intelligence / Profile preview

Asher Enterprises

South San Francisco, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Initial clinical data for etakafusp alfa (AB248) demonstrates potent and selective CD8+ T cell activation, early evidence of anti-tumor activity, and a well-tolerated safety profile in Phase 1 studies for solid tumors[2][4][8].

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: BiologicAntibodyCytokineAntibody-cytokine fusion protein
Industry: Biotech

Partnerships

AstraZeneca (clinical supply and combination trial of etakafusp alfa with rilvegostomig)Merck (KEYTRUDA/pembrolizumab combination studies)Lonza (GMP manufacturing partner)

Beyond the preview

Go deeper on Asher Enterprises.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asher Enterprises.

Explore the full profile